Fierce Biotech: Reversing the risk of sudden cardiac death with gene therapy

Fierce Biotech reports on a new study from Boston Children’s that could be the first human tissue model of catecholaminergic polymorphic ventricular tachycardia (CPVT), a potentially lethal form of arrhythmia that’s triggered by exercise or sudden emotional stress. Using the model, they developed a gene therapy procedure that aims to treat CPVT by restoring calcium regulation. Read more on Fierce Biotech.